Study Evaluating SKI-606 Administered to Healthy Subjects
Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SKI-606 Administered Orally to Healthy Subjects
1 other identifier
interventional
N/A
1 country
1
Brief Summary
Safety and tolerability of SKI-606 in healthy subjects; the influence of food intake on the same.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
Started Nov 2006
Typical duration for phase_1 healthy
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2006
CompletedFirst Submitted
Initial submission to the registry
November 29, 2006
CompletedFirst Posted
Study publicly available on registry
December 4, 2006
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2007
CompletedDecember 5, 2007
December 1, 2007
November 29, 2006
December 3, 2007
Conditions
Outcome Measures
Primary Outcomes (1)
Pharmacokinetics; safety and tolerability; influence of food.
Interventions
Eligibility Criteria
You may qualify if:
- Healthy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Unknown Facility
Utrecht, 3584 CJ, Netherlands
MeSH Terms
Interventions
Study Officials
- STUDY DIRECTOR
Medical Monitor
Wyeth is now a wholly owned subsidiary of Pfizer
- PRINCIPAL INVESTIGATOR
Trial Manager
For Netherlands, trials-NL@wyeth.com
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
November 29, 2006
First Posted
December 4, 2006
Study Start
November 1, 2006
Study Completion
August 1, 2007
Last Updated
December 5, 2007
Record last verified: 2007-12